

Idiopathic Intracranial Hypertension: Epidemiological, Clinical, and Therapeutic Characteristics in a Moroccan Tertiary Neurology Center – A Retrospective Study of 105 Patients.

Abstract

Background:

Idiopathic intracranial hypertension (IIH) is a neurological disorder characterized by increased intracranial pressure without an identifiable intracranial cause. The condition predominantly affects women of reproductive age and may lead to significant visual impairment if diagnosis and treatment are delayed. Data on IIH from North African populations remain limited.

Objective:

This study aimed to describe the epidemiological, clinical, radiological, and therapeutic characteristics of patients diagnosed with idiopathic intracranial hypertension in a tertiary neurology center in Morocco and to evaluate their clinical outcomes.

Methods:

We conducted a retrospective descriptive study over an 11-year period (January 2010 to April 2021) at the Neurology Department of Mohammed VI University Hospital in Marrakech. Patients diagnosed with IIH according to the revised modified Dandy criteria were included. Demographic data, clinical presentation, ophthalmological findings, neuroimaging results, cerebrospinal fluid characteristics, treatment modalities, and outcomes were analyzed.

Results:

A total of 105 patients were included, representing approximately 2% of neurological hospitalizations during the study period. The mean age was 29.7 ± 8.5 years, with a marked female predominance (female-to-male ratio: 10.6:1). Headache was present in all patients, followed by diplopia (50%), pulsatile tinnitus (48%), and visual disturbances (48%). Papilledema was observed in 96% of cases. Elevated cerebrospinal fluid opening pressure was documented in all patients with normal CSF composition. Brain magnetic resonance imaging revealed indirect signs of intracranial hypertension in the majority of patients, including empty sella, optic nerve sheath distension, and transverse sinus stenosis. Medical management, mainly acetazolamide therapy combined with therapeutic lumbar puncture, was effective in most cases. Surgical treatment was required in 21% of patients, primarily in fulminant cases with rapid visual deterioration. Visual improvement was observed in the majority of treated patients, although permanent blindness occurred in 4.7% of cases.

Conclusion:

Idiopathic intracranial hypertension predominantly affects young women and may lead to severe visual impairment if not diagnosed and treated promptly. Early recognition, appropriate neuroimaging, and

timely therapeutic intervention are essential to improve visual outcomes and reduce the risk of permanent vision loss.

Keywords: idiopathic intracranial hypertension; papilledema; lumbar puncture; magnetic resonance imaging; acetazolamide; visual loss; Morocco.

Idiopathic Intracranial Hypertension: Epidemiological, Clinical, and Therapeutic Characteristics in a Moroccan Tertiary Neurology Center – A Retrospective Study of 105 Patients

Introduction

Idiopathic intracranial hypertension (IIH) is considered an uncommon neurological disorder, with an estimated annual incidence ranging from 0.5 to 2 cases per 100,000 individuals in the general population. However, the incidence increases markedly among women of reproductive age with obesity, reaching up to 15–20 cases per 100,000 in some populations. Over the past decades, the incidence of IIH has risen in parallel with the global increase in obesity, suggesting a strong association between metabolic factors and disease development. These epidemiological trends highlight the growing clinical relevance of IIH as a potential cause of chronic headache and visual impairment worldwide [1–4].

IIH predominantly affects women of childbearing age, particularly those with overweight or obesity, and represents a potentially vision-threatening condition. Although once referred to as “benign intracranial hypertension,” this terminology has been abandoned due to the significant risk of irreversible visual loss and the substantial impact on quality of life. Visual impairment, chronic headaches, and cranial nerve palsies are common manifestations, underscoring the importance of early diagnosis and appropriate treatment.

The diagnosis of IIH is based on the revised modified Dandy criteria, which include papilledema, normal neurological examination except for cranial nerve abnormalities, normal cerebrospinal fluid (CSF) composition, absence of structural abnormalities on neuroimaging, and elevated CSF opening pressure. Advances in magnetic resonance imaging (MRI) and venography have improved diagnostic accuracy by identifying indirect radiological signs of raised intracranial pressure, such as empty sella, optic nerve sheath distension, posterior globe flattening, and transverse sinus stenosis.

Despite growing recognition of IIH worldwide, data from North African populations remain limited. Regional studies are essential to better characterize epidemiological patterns, clinical presentations, and treatment outcomes, particularly in healthcare settings with varying diagnostic and therapeutic resources.

The aim of this study was to describe the epidemiological, clinical, radiological, and therapeutic features of idiopathic intracranial hypertension in patients hospitalized at a tertiary neurology center in Morocco and to compare our findings with previously published data.

Materials and Methods

72 Study Design and Setting

73 We conducted a retrospective descriptive study over an 11-year period, from January 1, 2010, to April 1,
74 2021, at the Neurology Department of Mohammed VI University Hospital, Marrakech, a tertiary referral
75 center serving southern Morocco.

76 Study Population

77 All patients hospitalized during the study period with a diagnosis of idiopathic intracranial hypertension
78 were eligible for inclusion. The diagnosis was established according to the revised modified Dandy criteria.
79 Patients with incomplete medical records or evidence of secondary causes of intracranial hypertension
80 were excluded.

81 Data Collection

82 The following variables were analyzed: demographic characteristics (age and sex), medical history and risk
83 factors, clinical presentation, ophthalmological findings, neuroimaging findings, cerebrospinal fluid
84 opening pressure and composition, therapeutic management (medical treatment, lumbar puncture, and
85 surgical intervention), and short- and long-term outcomes.

86 All patients underwent ophthalmological evaluation within the first 24 hours of admission, including best-
87 corrected visual acuity assessment and fundus examination. Visual field testing was performed when
88 feasible.

89 Neuroimaging: Brain computed tomography (CT) was used as a first-line imaging modality in selected
90 cases. Brain MRI was performed in all patients to exclude secondary causes and to identify indirect signs of
91 intracranial hypertension. MR venography was used to assess venous sinus abnormalities.

92 Lumbar puncture was performed in the lateral decubitus position with measurement of CSF opening
93 pressure using a standardized technique. CSF samples were systematically analyzed for cytological and
94 biochemical abnormalities.

95 Statistical Analysis

96 Descriptive statistical analysis was performed using Microsoft Excel 2021. Categorical variables were
97 expressed as frequencies and percentages, while continuous variables were presented as mean $\pm$ standard
98 deviation.

99 Ethical Considerations

100 This study was conducted in accordance with the ethical standards of the institutional research committee
101 and the principles of the Declaration of Helsinki. The study protocol was approved by the ethics committee
102 of Mohammed VI University Hospital, Marrakech. Due to the retrospective nature of the study, the
103 requirement for informed consent was waived. Patient confidentiality and anonymity were strictly
104 maintained. The authors declare no conflict of interest.

105

106 **Results**

107 **Epidemiological Characteristics**

108 A total of 105 patients were included (Table 1), accounting for approximately 2% of neurological
109 hospitalizations during the study period. The mean age was 29.7 ± 8.5 years. There was a marked female
110 predominance, corresponding to a female-to-male ratio of 10.6:1. The most affected age group was
111 between 18 and 30 years, representing 57% of cases.

Variable	Value
Number of patients	105
Mean age (years ± SD)	29.7 ± 8.5
Age range (years)	12–73
Female sex	96 (91.4%)
Male sex	9 (8.6%)
Female-to-male ratio	10.6:1

112
113 Table 1. Demographic Characteristics of the Study Population
114 Legend: SD: standard deviation.

115
116 **Risk Factors and Medical History**

117 Obesity or overweight was documented in 33% of patients for whom body mass index was available.
118 Among these, 45% had morbid obesity. Oral contraceptive use was reported in 48% of female patients.
119 Endocrine disorders were present in 18% of cases, including diabetes mellitus, thyroid dysfunction, and
120 Cushing’s disease. Anemia was identified in eight female patients. Five patients were pregnant at the time
121 of diagnosis (Table 2).

Risk factor / condition	n (%)
Overweight or obesity	35 (33%)
Morbid obesity	16 (45% of obese patients)
Oral contraceptive use	46 (48% of women)
Endocrine disorders	19 (18%)
Anemia	8 (7.6%)
Pregnancy	5 (4.7%)

122
123 Table 2. Risk Factors and Associated Conditions

124 **Clinical Presentation**

125 Headache was the presenting symptom in all patients . Headaches were typically diffuse, pulsatile, and
126 more intense in the morning, often associated with neck pain. Visual disturbances were reported in 48% of
127 cases, including blurred vision and transient visual obscurations. Diplopia was observed in 50% of patients,
128 most commonly due to sixth cranial nerve palsy. Pulsatile tinnitus was reported by 48% of patients.

129 More than 60% of patients presented with an acute onset of symptoms, while 24% had a progressive
130 course with delayed consultation.

131 **Neurological and Ophthalmological Findings**

132 All patients were conscious with normal mental status. Apart from cranial nerve involvement, no focal
133 neurological deficits were observed. Cranial nerve VI palsy was the most frequent neurological finding.

134 Papilledema was present in 96% of patients (Table 3), predominantly bilateral and symmetric. Visual
135 acuity was reduced in 48% of cases, with four patients presenting with bilateral blindness at admission.

Finding	n (%)
Papilledema	101 (96%)
Bilateral papilledema	97 (92%)
Reduced visual acuity	50 (48%)
Bilateral blindness at presentation	4 (3.8%)
Sixth cranial nerve palsy	53 (50%)

136

137 Table 3. Ophthalmological and Neurological Findings

138 **Neuroimaging Findings**

139 Brain CT scans were performed in 37 patients and were normal in all cases. Brain MRI revealed indirect
140 signs of intracranial hypertension in the majority of patients, including empty sella, optic nerve sheath
141 distension, posterior globe flattening, and optic nerve tortuosity. Transverse sinus stenosis was identified
142 in a subset of patients on MR venography (Figure 1: a,b,c,d).




Figure 1. MRI indirect signs of intracranial hypertension:

- (a) empty sella;
- (b) posterior globe flattening and optic nerve sheath distension;
- (c) optic nerve tortuosity;
- (d) transverse sinus stenosis.

Cerebrospinal Fluid Findings

Elevated CSF opening pressure (>25 cmH₂O in adults and >28 cmH₂O in children) was documented in all patients. CSF composition was normal in all cases.

Treatment and Outcomes

All patients underwent therapeutic lumbar puncture. Medical treatment with acetazolamide was administered in nearly all cases, with potassium supplementation as needed (Table 4). Corticosteroids were used in selected cases, particularly before 2017. Surgical treatment, mainly ventriculoperitoneal shunting, was required in 21% of patients, primarily in fulminant forms with rapid visual deterioration.

Treatment/ outcome	n (%)
Therapeutic lumbar puncture	105 (100%)
Acetazolamide therapy	98 (93%)
Corticosteroid use	22 (21%)
Surgical treatment	22 (21%)
Visual improvement	61 (58%)
Recurrence	5 (4.7%)
Permanent blindness	5 (4.7%)

Table 4. Treatment Modalities and Outcomes

Short-term outcomes were favorable in most patients, with improvement in headache and visual symptoms. Visual acuity improved in 58% of patients with initial visual impairment. Long-term follow-up revealed complete recovery in the majority of patients within 3–6 months. Recurrence occurred in five patients. Permanent blindness was observed in 4.7% of cases.

Discussion

Idiopathic intracranial hypertension is a complex neurological disorder with heterogeneous clinical presentations and incompletely understood pathophysiological mechanisms. Our study provides a comprehensive overview of IIH in a large cohort of patients managed at a tertiary neurology center in Morocco and offers valuable insights into its epidemiological, clinical, radiological, and therapeutic characteristics.

Epidemiological Characteristics

The marked female predominance observed in our cohort (female-to-male ratio of 10.6:1) is consistent with previously published series, in which sex ratios range from 3:1 to 15:1 [1–4]. This predominance is classically attributed to hormonal, metabolic, and adipose tissue-related factors. The mean age of 29.7 years and the predominance of young adults between 18 and 30 years also align with international data, confirming that IIH is primarily a disease of women of childbearing age [5,6].

Although IIH is traditionally considered rare, its incidence has increased significantly over recent decades, largely paralleling the global rise in obesity [7]. In our series, IIH accounted for 2% of neurological hospitalizations, a proportion comparable to reports from other tertiary centers in both developed and developing countries [8,9].

Pathophysiological considerations

The exact pathophysiology of idiopathic intracranial hypertension remains incompletely understood. Several mechanisms have been proposed, including impaired cerebrospinal fluid (CSF) absorption at the level of the arachnoid granulations, increased intracranial venous pressure, and metabolic or hormonal factors associated with obesity. Recent studies have emphasized the potential role of transverse venous sinus stenosis, which may lead to increased venous pressure and impaired CSF drainage. In addition, obesity-related endocrine and inflammatory pathways may contribute to altered CSF dynamics and intracranial pressure regulation. These mechanisms are likely multifactorial and may vary among patients, reflecting the complex pathophysiology of the disease [5–8].

191 **Risk Factors and Associated Conditions**

192 Obesity remains the most consistently identified risk factor for IIH. In our cohort, one-third of patients
193 were overweight or obese, with a high proportion presenting with morbid obesity. Several studies have
194 demonstrated a strong association between elevated body mass index and poor visual outcomes, with a
195 higher risk of severe visual loss as BMI increases [9,10,17]. These findings support the hypothesis that
196 adipose tissue plays an active role in IIH pathophysiology through endocrine and metabolic mechanisms.

197 Endocrine disorders, including diabetes mellitus, thyroid dysfunction, and Cushing's disease, were
198 observed in a subset of patients. These associations have been previously reported and suggest that
199 metabolic dysregulation may contribute to altered cerebrospinal fluid (CSF) dynamics [11].

200 Iron-deficiency anemia was identified in eight patients in our series. An association between anemia and
201 IIH has been increasingly recognized, with several studies reporting rapid clinical and visual improvement
202 following correction of anemia [12,13]. Although the underlying mechanism remains unclear, impaired
203 oxygen delivery and altered cerebral venous hemodynamics have been proposed.

204 **Clinical Presentation**

205 Headache was the most common presenting symptom, reported by all patients, consistent with the
206 literature [14]. The typical characteristics—diffuse, pulsatile headaches with morning predominance—
207 reflect raised intracranial pressure. Visual disturbances and diplopia were also frequent, highlighting the
208 potential for severe visual morbidity.

209 Sixth cranial nerve palsy was the most common neurological deficit observed, a well-recognized
210 manifestation of increased intracranial pressure [15]. Rare cranial nerve involvements, including third and
211 fourth nerve palsies, were also noted, emphasizing the variability of neurological presentations in IIH.

212 **Ophthalmological Findings and Visual Prognosis**

213 Papilledema was present in 96% of patients, confirming its role as a cardinal diagnostic sign of IIH.
214 However, a small proportion of patients presented without papilledema, a phenomenon increasingly
215 described in the literature as "IIH without papilledema" [16]. These cases pose a diagnostic challenge and
216 underscore the importance of integrating clinical, radiological, and CSF findings.

217 Visual impairment was common in our cohort, with nearly half of the patients presenting with reduced
218 visual acuity. Permanent blindness occurred in 4.7% of cases, a rate comparable to that reported in large
219 series [16,17]. Delayed diagnosis and delayed initiation of appropriate treatment were the main
220 contributors to poor visual outcomes, reinforcing the need for early recognition and close ophthalmological
221 monitoring.

222 **Neuroimaging and Pathophysiological Considerations**

223 Brain MRI played a crucial role in diagnosis, revealing indirect signs of raised intracranial pressure in most
224 patients. Empty sella, optic nerve sheath distension, posterior globe flattening, and optic nerve tortuosity
225 are well-established imaging markers of IIH [9,12].

226 Transverse sinus stenosis was identified in a subset of patients. Venous sinus stenosis is now recognized as
227 a common finding in IIH and is thought to contribute to impaired CSF absorption by increasing venous
228 pressure [18]. However, the causal relationship remains debated, as such stenoses may resolve after
229 normalization of intracranial pressure or persist despite clinical improvement .

230 **Therapeutic Management**

231 Medical management remains the cornerstone of IIH treatment. In our series, acetazolamide was the first-
232 line therapy and was well tolerated in most patients. Its efficacy in reducing CSF production and improving
233 visual outcomes has been demonstrated in randomized controlled trials [19,20].

234 Therapeutic lumbar puncture was systematically performed and provided symptomatic relief in many
235 patients. However, repeated lumbar punctures were required in a minority of cases and were insufficient
236 in fulminant forms.

237 Surgical intervention was necessary in 21% of patients, primarily those with fulminant IIH and rapidly
238 progressive visual loss. Ventriculoperitoneal shunting was the most commonly used procedure, with
239 favorable outcomes in the majority of cases. These findings are consistent with current recommendations
240 advocating early surgical intervention in patients with vision-threatening disease refractory to medical
241 therapy [15,18].

242 **Study Limitations**

243 This study has several limitations. First, the retrospective design may introduce selection bias and limit the
244 completeness of some clinical data. Second, body mass index and long-term ophthalmological follow-up
245 were not available for all patients. Third, the study was conducted in a single tertiary referral center, which
246 may limit the generalizability of the results to the general population. Nevertheless, the relatively large
247 sample size and the long study period provide valuable insights into the characteristics of idiopathic
248 intracranial hypertension in a North African population.

249 **Study Strengths**

250 Despite these limitations, our study represents one of the largest series of idiopathic intracranial
251 hypertension reported from Morocco and North Africa. The relatively large number of patients, the long
252 study period, and the comprehensive clinical, radiological, and therapeutic evaluation provide valuable
253 data that contribute to the limited regional literature on this condition.

254 **Clinical Implications**

255 Early recognition of idiopathic intracranial hypertension is essential to prevent irreversible visual loss.
256 Clinicians should maintain a high index of suspicion in young women presenting with chronic headache,
257 visual disturbances, and papilledema, particularly in the presence of obesity or endocrine disorders.
258 Prompt neuroimaging to exclude secondary causes, followed by lumbar puncture with measurement of CSF
259 opening pressure, remains essential for diagnosis. Early initiation of medical therapy, particularly
260 acetazolamide, combined with weight management and close ophthalmological monitoring, plays a key
261 role in preserving visual function and preventing long-term complications [5,9,10].

262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291

Conclusion

Idiopathic intracranial hypertension is a potentially vision-threatening neurological disorder that predominantly affects young women. Our study highlights the clinical diversity and the significant risk of visual impairment associated with delayed diagnosis. Early recognition, appropriate neuroimaging, and prompt initiation of treatment are essential to improve outcomes. Greater awareness of this condition among clinicians may help reduce diagnostic delays and prevent permanent visual loss.

Declaration

Ethical Approval And Consent To Participate

It is a retrospective report and the authors respected the anonymity of the patients and his archived medical file. Consequently, only the agreement of the head of the department (KN) was required and obtained.

Consent For Publication

Not applicable.

Competing Interests

The authors declare no potential conflicts of interest.

Funding

No funding was obtained for the present study.

Authors' Contributions

All authors participated in patient care. They all contributed to the writing of the manuscript. CM, KN, and LN approved the final version.

Acknowledgements:

The data used during the study are available on request from the corresponding author.

The authors wish to thank the multidisciplinary staff who contributed to the diagnosis and care of the patients (neurologist, ophthalmologist, radiologists, hematologists, physiotherapists and nurses).

292

293

294 **References**

- 295 1. KapilG.Kapoor.
296 MoreThanMeetsTheEyeRedefiningIdiopathicIntracranialHypertension.
297 International Journal of Neuroscience, 120, 471–482, 2010.
298 DOI10.3109/00207451003760098
299
- 300 2. CorbettJJ,Thompson HS.
301 Therationalmanagementofidiopathicintracranialhypertension. Arch
302 Neurol. 1989 ; 46 :1049–51.
303 DOI10.1001/archneur.1989.00520460025008
304
- 305 3. Dandy,W.E.
306 Intracranialpressurewithoutbraintumor:Diagnosisandtreatment. Annals of
307 Surgery, 1937, 106, 492– 513. DOI
308 10.1097/00000658-193710000-00002
- 309 4. Foley,J.
310 Benignformsofintracranialhypertension:“Toxic”and“otitic”hydrocephalus. Brain,
311 1955, 78, 1–41. DOI 10.1136/jnnp.19.1.28
- 312 5. Digre.
313 Three Current Controversies in Idiopathic Intracranial Hypertension Neuro-
314 Ophthalmology, 33, 93–99, 2009. DOI 10.1080/01658100902930537.
- 315 6. DeborahI.Friedman,GrantT.
316 LiuandKathleenB.Digre.Reviseddiagnosticcriteriaforthepseudotumorcerebri syndrome in
317 adults and children. Neurology 2013 ; 81 ;1159-1165. DOI
318 10.1212/WNL.0b013e3182a55f17.
- 319 7. Friedman
320 DI,Jacobson:Diagnosticcriteria for idiopathicintracranial hypertension. Neurology 2002 ; 59
321 :1492–1495. DOI10.1212/01.wnl.0000029570.69134.1b.
- 322 8. DrMohamedAmineDERDOUR
323 STÉNOSEDUSINUSTRANSVERSEETHYPERTENSIONINTRACRANIENNEIDIOPATHIQUE:aspectsdi
324 agnosticsetvaleurpronostique2017 ; [http://www.sfoonline.fr/session/media/stenose-du-sinus-](http://www.sfoonline.fr/session/media/stenose-du-sinus-transverse-et-hypertension-intracranienne-idiopathique-aspects)
325 [transverse-et-hypertension-intracranienne-idiopathique-aspects.](http://www.sfoonline.fr/session/media/stenose-du-sinus-transverse-et-hypertension-intracranienne-idiopathique-aspects)
- 326 9. BidotS,BruceBB.

- 327 Update on the diagnosis and treatment of idiopathic intracranial hypertension. *Semin Neurol* 2015 ;35
328 (5) :527-38. DOI 10.1055/s-0035-1563569.
- 329
- 330 10. Riggeal BD, Bruce BB, Saindane AM, Ridha MA, Kelly LP, Newman NJ, et al.
331 Clinical course of idiopathic intracranial hypertension with transverse sinus stenosis. *Neurology*
332 2013 ;80(3) :289-95. DOI 10.1212/WNL.0b013e31827debd6
- 333
- 334 11. Patsalides A, Oliveira C, Wilcox J, Brown K, Grover K, Gobin YP, et al.
335 Venous sinus stenting lowers the intracranial pressure in patients with idiopathic intracranial
336 hypertension. *J Neurointerv Surg* 2019 ;11(2) :175-8. DOI 10.1136/neurintsurg-2018-014032.
- 337
- 338 12. Lenck S, Radovanovic I, Nicholson P, Hodaie M, Krings T, Mendes Pereira V.
339 Idiopathic intracranial hypertension: the venoglymphatic connections. *Neurology* 2018
340 ;91(11):515-22. DOI 10.1136/neurintsurg-2018-014032. DOI 10.1212/WNL.0000000000006166.
- 341 13. Kanagalingam S, Subramanian P.
342 Endoprosthesis of sinus venous cerebral for pseudotumor cerebral: a review. *Saoudien J*
343 *Ophthalmol*. 2015 ;29(1) :3-8. DOI 10.1016/j.sjopt.2014.09.007.
- 344 14. Corbett JJ, Thompson HS.
345 Therapeutic management of idiopathic intracranial hypertension. *Arch Neurol*. 1989; 46:1049-51.
- 346
- 347 15. James H Manfield , Kenny K-H Yu , Evangelos Efthimiou , Ara Darzi , Thanos Athanasiou , Hutan Ashrafian :
348 Chirurgie bariatrique ou perte de poids non chirurgicale pour l'hypertension intracrânienne idiopathique .
349 Une revue systématique et une comparaison des méta- analyses. *Surg obèse*. 2017, 27:513-521.
350 DOI 10.1007/s11695-016-2467-7.
- 351
- 352 16. Szeuwka AJ, Bruce BB, Newman NJ, Biousse V.
353 Hypertension intracrânienne idiopathique: relation entre l'obésité et les résultats visuels. *J*
354 *Neuroophthalmol*. 2013 ;33(1) :4-8. DOI 10.1097/WNO.0b013e31823f852d
- 355
- 356 17. Ko MW, Chang SC, Ridha MA, et al.
357 Prise en charge et récidive dans l'hypertension intracrânienne idiopathique: une étude cas-
358 témoins. *Neurologie*. 2011 ;76(18) :1564-1567.
- 359 18. Jensen R, Radojicic A, Yri H.
360 Le diagnostic et la prise en charge de l'hypertension intracrânienne idiopathique et
361 des maux de tête associés. *Neurol Sci*. 2013 ;34(suppl 1) : S147-S149. DOI
362 10.1177/1756285616635987.
- 363
- 364 19. Valérie Biousse , Beau B Bruce , Nancy J Newman: Anemia and papilledema. *Am J Ophthalmol*. 2003,

365
366
367
368
369

135:437-46. DOI 10.1016/s0002-9394(02)02062-7

20. Saket S T, Jiwan K, Yatika C et al .
Navigating the Enigma: A Comprehensive Review of Idiopathic Intracranial Hypertension; Cureus.
2024 Mar 16;16(3):e56256. DOI 10.7759/cureus.56256. eCollection 2024 Mar.

UNDER PEER REVIEW IN IJAR

UNDER PEER REVIEW IN IJAR